Of the 830 patients who met study inclusion criteria, 103 were excluded for previous treatment, 15 for significant comorbid eye conditions, 16 for correctional facility status, and 134 for deceased status during study period (
n = 268). From our review, we found 562 DR treatment-naive patients seen for DR between January 2014 and December 2020 who met inclusion criteria. Baseline characteristics are shown below, with a mean age of 56.5 ± 11.4 years and the majority (60.8%) identifying as Hispanic (
Table 1). Most (70.3%) had treatment for hypertension. Among the 527 patients with an HbA1c in their EMR, the average of their most recent was 8.5 ± 2.0, ranging from 4.6 to 14.2.
Table 2 shows comparison of patient characteristics by DR severity at initial visit. Spanish as a primary language was more prevalent in those who presented with PDR versus no retinopathy (58.6% vs. 33.8%). In addition, 71.2% of patients with PDR had a PCP compared to 92.4% of the no retinopathy group and 87.6% of the mild NPDR group. Of patients with a PCP, 69.4% (327/471) had a referral while those without a PCP had a referral rate of 48.9% (44/90;
P < 0.001). Highest lack of referral was seen in the PDR group (47.2%). Only 18.8% of the PDR group were fully compliant with PCP appointments compared to 40.9% in the no DR group and 36.8% of the mild NPDR group. Uninsured status was highest in the PDR group at 19.2%. Higher HbA1cs, with means of 8.7, were found in both the moderate/severe NPDR and PDR groups, compared to the no DR group with a mean A1c of 8.2 (
P = 0.03 and
P = 0.04, respectively). Finally, the rate of kidney disease was highest in the PDR group at 49.6%. The final multivariable model included sex, age, primary language, kidney disease, having a PCP, and insurance status. Primary language, kidney disease, having a PCP, and insurance status all remained significant. In the sensitivity analysis that also included duration of diabetes, HbA1c, and a combined variable of having a PCP and adherence with PCP, the variables of primary language, kidney disease, and insurance status remained significant. Sex, age, duration of diabetes, HbA1c, and the combined variable of having a PCP and adherence were not significant.
Eye-level data of outcomes for the 1,124 eyes at final visit are presented in
Table 3 by DR status of that specific eye at initial visit. Within the advanced DR eyes, a high portion of eyes with PDR received treatment, with 77.9% receiving panretinal photocoagulation (PRP), 60.4% receiving injections, 34.2% receiving pars plana vitrectomy (PPV), and 27.5% receiving cataract surgery. The moderate/severe NPDR eyes received less treatment but still at higher rates than the early presentation group, with 17.2% receiving PRP, 26.2% receiving injections, 2.3% receiving PPV, and 20.4% receiving cataract surgery. In comparison, within the eyes with early presentation, the no DR and mild DR eyes had 4.1% and 3.6% receiving PRP, 7.6% and 4.4% receiving injections, 2.9% and 0.5% receiving PPV, and 20.6% and 16.0% receiving cataract surgery, respectively.
The mean follow-up time in months from initial to final visit was longest for patients with no DR, 33.8 ± 14.4, and shortest for patients with PDR, 17.9 ± 14.8, and was significantly different across all four groups (
P < 0.0001). The mild NPDR group's mean follow-up was 24.8 ± 15.8, and the moderate/severe group was 19.8 ± 16.5. At initial visit, the mean VAs in logMAR values for the delayed presentation groups of moderate/severe NPDR and PDR were 0.40 ± 0.44 (20/50) and 0.96 ± 0.82 (20/182), respectively, in comparison to the early presentation groups of no DR and mild NPDR with VAs of 0.36 ± 0.51 (20/46) and 0.31 ± 0.38 (20/41) (
P < 0.001). There was no significant difference across groups in VA decline from initial to final visit (
P = 0.20). However, PDR eyes had the worst mean final VA at 0.87 ± 0.80 (20/148), while the no DR, mild NPDR, and moderate/severe NPDR groups had mean VAs of 0.33 ± 0.46 (20/43), 0.31 ± 0.46 (20/41), and 0.36 ± 0.42 (20/46), respectively (
P < 0.001;
Table 3).